Company Overview
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -71.00% |
| 6 Months: | -12.13% |
| 3 Months: | -3.22% |
| 1 Month: | +5.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 75.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TIL Instil Bio, Inc. PHARMA | 7.82 | -1.78 | $53.04M | 0.00% | -26.15% | -25.33% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.00K | 42.00K | 52.00K | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.48M | 12.90M | 15.02M | 9.56M | 6.02M |
| Operating Income | -3.86M | -4.59M | -7.71M | -23.40M | -35.38M | -43.02M | -54.29M | -58.72M | -56.65M | -58.45M | -20.99M | -66.72M | -23.95M | -14.13M | -23.63M | - | -14.48M | -12.90M | -15.02M | -9.56M | -6.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.82M | -19.80M | -11.99M | -7.40M | -2.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 886.00K | 1.58M | 1.58M | 776.00K | 1.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.20M | -21.39M | -13.59M | -8.19M | -4.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.09M | -9.20M | -7.26M | -23.13M | -35.31M | -43.01M | -54.12M | -58.99M | -56.22M | -57.07M | -18.66M | -67.43M | -24.30M | -14.92M | -23.02M | - | -28.20M | -21.39M | -13.59M | -8.19M | -4.20M |
| Diluted EPS | -0.31 | -0.55 | -0.43 | -0.66 | -0.27 | -0.33 | -0.42 | -0.46 | -0.43 | -8.77 | -2.87 | -10.37 | -3.74 | -2.29 | -3.54 | -1.82 | -4.32 | -3.24 | -2.01 | - | -0.62 |
| R&D Expense | 2.01M | 2.24M | 4.91M | 14.42M | 21.19M | 29.06M | 39.17M | 41.50M | 39.66M | 20.67M | 8.46M | 8.49M | 7.26M | 2.92M | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 138.00K | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 203.29M | 87.16M | 56.05M | 51.96M |
| Operating Income | -33.64M | - | -203.29M | -87.16M | -56.05M | -51.96M |
| EBITDA | - | - | -217.38M | -147.12M | -62.53M | -65.80M |
| Interest Expense | - | - | 1.88M | 4.21M | 8.00M | 5.04M |
| Pretax Income | - | - | -225.25M | -156.09M | -74.14M | -71.37M |
| Tax Provision | - | 39.00K | -2.07M | 0 | - | - |
| Net Income | -37.74M | - | -223.18M | -156.09M | -74.14M | -71.37M |
| Diluted EPS | -2.36 | - | -34.40 | -24.00 | -11.39 | -10.70 |
| R&D Expense | 19.40M | 107.25M | 141.06M | 39.60M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 319.01M | - | 482.13M | 325.63M | 263.57M | 203.52M |
| Current Assets | - | - | - | 269.38M | 160.76M | 124.47M | 191.43M |
| Cash & Equivalents | - | 241.71M | - | 43.72M | 9.20M | 8.80M | 6.64M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 848.00K |
| Total Liabilities | - | 26.64M | - | 118.52M | 99.80M | 94.13M | 89.66M |
| Current Liabilities | - | 13.28M | - | 32.79M | 10.56M | 7.90M | 4.84M |
| Long Term Debt | - | - | - | 72.35M | 81.43M | 84.19M | 84.81M |
| Total Debt | - | - | - | 79.90M | 86.05M | 86.89M | 85.18M |
| Total Equity | -6.89M | -39.60M | - | 363.61M | 225.83M | 169.44M | 113.87M |
| Shares Outstanding | - | - | - | 6.50M | 6.50M | 6.53M | 6.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.62M | - | -180.16M | -82.03M | -55.70M | -36.62M |
| Investing Cash Flow | -51.12M | - | 114.54M | 41.13M | 53.97M | 25.48M |
| Financing Cash Flow | 313.05M | - | 71.89M | 8.08M | 1.75M | 7.29M |
| Capital Expenditure | -50.82M | - | -84.59M | -20.66M | -10.00M | -10.00M |
| Free Cash Flow | -80.43M | - | -264.75M | -102.69M | -65.70M | -46.62M |
| Net Change in Cash | - | - | 6.26M | -32.82M | 33.00K | -3.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -24,379.7% | - | - | - | - | - |
| Net Margin % | -27,346.4% | - | - | - | - | - |
| ROE % | 95.3% | - | -61.4% | -69.1% | -43.8% | -62.7% |
| ROCE % | -11.0% | - | -45.2% | -27.7% | -21.9% | -26.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Curative Ventures V LLC | 28.00% | 1.90M | $13.46M |
| 2 | BML Capital Management, LLC | 9.52% | 645.60K | $4.58M |
| 3 | Vivo Capital, LLC | 4.32% | 292.74K | $2.08M |
| 4 | UBS Group AG | 2.62% | 177.42K | $1.26M |
| 5 | Vanguard Capital Management LLC | 2.41% | 163.74K | $1.16M |
| 6 | Millennium Management Llc | 1.98% | 134.57K | $954.14K |
| 7 | Kalehua Capital Management LLC | 1.47% | 99.60K | $706.16K |
| 8 | Blackrock Inc. | 0.82% | 55.50K | $393.52K |
| 9 | Renaissance Technologies, LLC | 0.74% | 50.30K | $356.63K |
| 10 | Nomura Asset Management International Inc | 0.74% | 50.00K | $354.50K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TIL
TLRY Stock Extends Green Run: Tilray Funds Lyphe Buyout And Debt Reduction With 1.6M New Shares - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPdTFoUWhfUmxDMm9LemZsN3ZpZ2RoTUp0MGo0UzhNWF83VmcyZENGLVVzR08tbmlING1GSFZtYVR3bEpJNkdrRFpVc1A4ZC1QQkhJWlJhR3J6ZVE5Mmt2RXpMZlFMR0hzVXZfZ1Vna3hsYnhHVmJ6REpkSlBVaTI5aW9ONXdyZVRQOGZRSm…
(TIL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNb3hjNHUwNFNkVzZnbllRMjJqektTVVBMNVhLaThkanBDWXZUUV9PWTZRczQyQ0JuU2YzNlZTX0Z2QjhRZlJWMmwybUlYUkJQZ1k0NU81eWFwaENDbkxDOUJmcXBHd1FCVE0wMlg2d2prMnJ4UEtCZDNtNFRSc2VXSVp3b1dJNXl2Y3FhbX…
Instil Bio expects $69.9M cash to fund plan beyond 2027 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPbUdta0NnU3B3ckZyRmFsbklNTHRkbk95QmNtSmpWR1RZdG1CZFNpb09qZUd0YllGMGhrQzVlaHVudWZFd0hZam5SR2ExZ3FJV2I2QzA3T3gxM2k3TkQ0c0ttNjZyakJpdVVIQlZaZWQ5d1Zuc0FBUzkyNnZzWlhaOV96aU1lZGhlZnlISn…
Instil Bio Reports $4.3 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNaXk2dTRDSVc1NUNHdEF2U1hveFh0Mk8zVDJ3bnpVdlBpdVNTcTN3bmIzTmw5UDAxbFB1amd1OUtqX1hZY185eVJVR1BlU2o4dmk1dWJQUTk3aVZrUTAxSXBiTk9uQ3lwSkZvWnoxa2pnNEtpYzY0YXhobmtfMmkzTkZaS1RLRWlWYW1MbG…
Time In Force: 6 Order Types Explained with Examples - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE5tNWZVV0d5YTNwbjNILXdUaWJ4M0tweW5wanJEdnVzTEZDQWhNT2hqN0U3SGd1QV9UdlZ0VE1aQWhSR1NULWlCTnVlTm4zUzVpeU9WZnpiQm1DNE04aVpKOHE2c2o?oc=5" target="_blank">Time In Force: 6 Order Types Exp…
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNZUxxQ3ZwM0drd3IxOTBkb09KdXplcG5Wa2ZyNW1xV0twTU50S05UUHFUZ29RdnE5LThOdmJLbEhEYVVSdmdYdFhfeXZzRVdnR29YZmpGZXNHZ25lUDFqUWF6QXdtMWt1RnhNcm5WX1ZuWWtrdy1jM25oa1FIcUVrT2ZVcw?oc=5" targe…
TIL — Frequently Asked Questions
What is the current share price of Instil Bio, Inc. (TIL)?
As of 2026-09-19 21:16 PDT, Instil Bio, Inc. (TIL) trades at $7.82 on NasdaqCM. Its 52-week range is $6.66 to $31.50.
What is the market capitalisation of TIL?
Instil Bio, Inc. (TIL) has a market capitalisation of $53.04M on NasdaqCM.
What is the P/E ratio of TIL?
TIL trades at a trailing price-to-earnings (P/E) ratio of -1.78. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.45.
What is the return on equity (ROE) of TIL?
TIL has a return on equity (ROE) of -25.33%. Its return on capital employed (ROCE) is -26.15%.
Is TIL a good stock to buy?
This page provides a data-driven analysis of Instil Bio, Inc. (TIL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.